


Gestrinone

Chemical Properties

CAS No. :	16320-04-0
Formula:	C ₂₁ H ₂₄ O ₂
Molecular Weight:	308.41
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Gestrinone (R 2323) is a synthetic androgen receptor agonist and ER and progesterone receptor antagonist used to treat endometriosis. It inhibits leiomyoma cells with an IC ₅₀ of 43.67 μM.
Targets(IC ₅₀)	Estrogen Receptor/ERR, Estrogen/progestogen Receptor
In vivo	Mifepristone combined with gestrinone had satisfactory clinical therapeutic effects on endometriosis by reducing hormone levels and improving pregnancy outcomes[1].
Animal Research	A total of 150 endometriotic patients were randomly divided into a control group and a treatment group (n=75). The control group began to orally take gestrinone capsules on the second day after menstruation started (2.5 mg/time, twice/week). The treatment group orally took mifepristone tablets (12.5 mg/time, once/day), and the dosage and administration of gestrinone capsules were the same as those of the control group. After 24 weeks of consecutive treatment, the clinical therapeutic effects of the two groups were assessed, and the pelvic symptom score, clinical sign score, serum sex hormone levels and pregnancy outcomes were compared[1].

Solubility Information

Solubility	DMSO: 50 mg/mL (162.12 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.48 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.2424 mL	16.2122 mL	32.4244 mL
5 mM	0.6485 mL	3.2424 mL	6.4849 mL
10 mM	0.3242 mL	1.6212 mL	3.2424 mL
50 mM	0.0648 mL	0.3242 mL	0.6485 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Hui-Ling X , Ning Y , Jing W , et al. Therapeutic effects of mifepristone combined withGestrinone on patients with endometriosis[J]. Pakistan Journal of Medical Sciences, 2016, 32(5).

Song J, Wang Y, Yu L,et al.Clinical comparison of mifepristone and gestrinone for laparoscopic endometriosis[J]. Pak J Pharm Sci. 2018 Sep;31(5(Special)):2197-2201.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481